Abstract
Dementia has posed a significant public health challenge for aging populations in developed countries for many years. Alzheimer's Disease (AD) is the most prevalent cause of dementia, marked by cognitive and behavioral irregularities resulting from cholinergic dysfunction, a progressive and irreversible neurodegenerative disorder. Restoring cholinergic neurotransmission can alleviate impaired cognitive and behavioral symptoms in AD patients. Donepezil (DNP) is an acetylcholinesterase inhibitor utilized to treat mild to moderate AD symptoms. Niosomes, non-ionic surfactant vesicles, present an array of benefits as drug delivery systems, including stability, non-immunogenicity, permeation potential, and controlled release ability. In this research, we prepared, characterized, radiolabeled with 99mTc, and evaluated DNP-loaded niosome formulations as radiopharmaceuticals for brain imaging agents. The findings suggest that this innovative radiopharmaceutical ([99mTc]Tc-formulation) has the potential to serve as a promising alternative imaging agent for neurological disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
